Cited by 2,785Pharmacogenetics and Drug MetabolismDrug-Induced Hepatotoxicity and ProtectionMetal-Catalyzed Oxygenation Mechanisms

The DOI matches its Crossref record.

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians

Shimada, T, Yamazaki, H, Mimura, M, Inui, Y, Guengerich, F P·1994·The Journal of Pharmacology and Experimental Therapeutics

DOI 10.1016/s0022-3565(25)22379-5

Open this paper in CoChat — free account

Abstract

Interindividual variations in the level and activity of cytochrome P-450 enzymes were investigated in the liver microsomes of 30 Japanese and 30 Caucasian patients. The P-450 enzymes used in this study included P-450 1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A, and the monooxygenase activities determined were 13 typical P-450 substrates and 9 procarcinogens. Although the total P-450 content was higher in Caucasian (mean, 0.43 nmol/mg of protein) than in Japanese populations (mean, 0.26 nmol/mg of protein), the relative levels (percent of total P-450) of individual forms of P-450 determined immunochemically were not very different except that P-450 2A6 and 2B6 levels were higher in the Caucasians. About 70% of liver P-450 could be accounted for by P-450 1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A proteins, and P-450 3A (about 30% of total P-450) and 2C (about 20%) enzymes were found to be the major forms. Considerable levels of P-450 1A2 (about 13%) and 2E1 (about 7%) could be determined, whereas the P-450 2A6 (about 4%), 2D6 (about 2%) and 2B6 (< 1%) were the minor P-450 forms. Differences in some of the P-450 1A2-, 2A6-, 2D6-, 2E1- and 3A4-dependent activities were observed in Japanese and Caucasian populations. No clear sex-related differences in individual P-450 contents and drug- and carcinogen-metabolizing activities were detected in 60 human samples, except that P-450 1A2-dependent activities were found to be higher in mean than in women in the Caucasian population only. A single neonate sample tended to be lower in P-450 1A2-, 2A6- and 2E1-dependent activities. In contrast to rat counterparts, we could not detect apparent developmental changes in P-450 content and activity in humans between 12 and 73 years old. Thus, the results presented in this study provide useful information for the study of drug biotransformation in humans and for the basis of drug toxicities, carcinogenesis and teratogenesis.

Integrity signals

Registry

Crossref · 10.1016/s0022-3565(25)22379-5

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 401–500 of 1,005

The Role of P-Glycoprotein and Canalicular Multispecific Organic Anion Transporter in the Hepatobiliary Excretion of Drugs
Kusuhara, H., Suzuki, H., & Sugiyama, Y. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970100b · Cited by 117
Metabolism of Drugs by Cytochrome P450 3A Isoforms
Moltke, L. L., Greenblatt, D. J., Schmider, J., Harmatz, J. S., & Shader, R. I. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199500291-00007 · Cited by 118
Benzydamine N‐oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity
Störmer, E., Roots, I., & Brockmöller, J. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00296.x · Cited by 119
A Phase I study of CHS 828 in patients with solid tumor malignancy.
Hovstadius, P., Larsson, R. L., Jonsson, E., Skov, T., Kissmeyer, A., Krasilnikoff, K., Bergh, J. C. S., Karlsson, M. O., Lönnebo, A., & Ahlgren, J. (2002) · PubMed · Cited by 119
Moving towards dose individualization of tyrosine kinase inhibitors
Klümpen, H., Samer, C. F., Mathijssen, R. H. J., Schellens, J. H. M., & Gurney, H. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.08.006 · Cited by 120
Interindividual Variability of Methadone Response
Li, Y., Kantelip, J., Schieveen, P. G., & Davani, S. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256276 · Cited by 117
Potential anticancer role of colchicine-based derivatives
Kumar, A., Sharma, P. R., & Mondhe, D. M. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000464 · Cited by 122
Genetics of the Variable Expression of CYP3A in Humans
Wojnowski, L. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00019 · Cited by 117
“liver, where it accounts for 30–60% of total cytochrome P450.(33) The individual hepatic expression levels of the CYP3A4 protein varies up to 90-fold.”
Background
Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1
Clemente, M. G., Meloni, A., Obermayer–Straub, P., Frau, F., Manns, M. P., & Virgiliis, S. D. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70484-6 · Cited by 118
Role of polymorphic human cytochrome P450 enzymes in estrone oxidation
Cribb, A. E., Knight, M. J., Dryer, D., Guernsey, J., Hender, K., Tesch, M., & Saleh, T. M. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0801 · Cited by 118
“When the relative intrinsic clearances of the various enzymes were corrected for the differing expression levels in the typical human liver (51, 52), the predicted contribution from CYP1A2 was eight times higher than other CYP enzymes (Table 5).”
Background
In vitro and in vivo assessment of herb drug interactions
Venkataramanan, R., Komoroski, B. J., & Strom, S. C. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.021 · Cited by 118
Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the 3A subfamily
Onof, S., Hatanaka, T., Miyazawa, S., Tsutsui, M., Aoyama, T., Gonzalez, F. J., & Satoh, T. (1996) · Xenobiotica · doi:10.3109/00498259609050260 · Cited by 118
Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans
Carlile, D. J., Hakooz, N., Bayliss, M. K., et al. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00935.x · Cited by 118
Animal models of toxicology testing: the role of pigs
Helke, K. L., & Swindle, M. M. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.739607 · Cited by 121
“Female minipigs have two to four times higher enzyme activity than males, however the opposite is true for Caucasian humans [20,71].”
Background
CYP3A genetics in drug metabolism
Eichelbaum, M. F., & Burk, O. (2001) · Nature Medicine · doi:10.1038/85417 · Cited by 117
Cytochrome P450 and Non–Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics
Foti, R., & Dalvie, D. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.071753 · Cited by 118
“Protein data were included from both Western blot and mass spectrometry–based methods (Shimada et al., 1994; Overby et al., 1997; Richardson et al., 1997; Lasker et al., 1998; Zanger et al., 2001; Coller et al., 2002; Lin et al., 2002; Lamba et al., 2003; Westlind-Johnsson et al., 2003; Koukouritaki et al., 2004; Rett…”
Method
Impact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used Drugs
Hirota, T., Eguchi, S., & Ieiri, I. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rv-085 · Cited by 115
Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
Saiz‐Rodríguez, M., Almenara, S., Navares‐Gómez, M., Ochoa, D., Román, M. C., Zubiaur, P., Koller, D., Santos, M., Mejía-Abril, G. P., Borobia, A. M., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8040094 · Cited by 118
“CYP3A4 protein liver content and activity show an important inter-individual variation ranging from 10 to >100 fold [11,46,86].”
BackgroundInfluential
Hepatic drug metabolism and transport in patients with kidney disease
Nolin, T. D., Frye, R. F., & Matzke, G. R. (2003) · American Journal of Kidney Diseases · doi:10.1016/j.ajkd.2003.07.019 · Cited by 116
The Role of Cytochrome P450 3A4 in Alfentanil Clearance
Kharasch, E. D., Russell, M., Mautz, D. S., Thummel, K. E., Kunze, K. L., Bowdle, A. T., & Cox, K. (1997) · Anesthesiology · doi:10.1097/00000542-199707000-00006 · Cited by 112
Breath testing for human liver function assessment
Armuzzi, A., Candelli, M., Zocco, M. A., Andréoli, A., LORENZO, A. D., Nista, E. C., Miele, L., Cremonini, F., Cazzato, I. A., Grieco, A., et al. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01374.x · Cited by 114
An Interethnic Comparison of Polymorphisms of the Genes Encoding Drug-Metabolizing Enzymes and Drug Transporters: Experience in Singapore
Chowbay, B., Zhou, S., & Lee, E. J. D. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-28805 · Cited by 119
“CYP1A2 is one of the major CYPs in human liver (13%), while CYP1A1 is mainly expressed in human lung, placenta, and lymphocytes (Rendic, 2002; Rendic and Di Carlo, 1997; Shimada et al., 1994).”
BackgroundInfluential
In Vitro Inhibition and Induction of Human Hepatic Cytochrome P450 Enzymes by Modafinil
Robertson, P., DeCory, H. H., Madan, A., & Parkinson, A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15146-x · Cited by 114
“In the case of CYP2B6, the activity of the enzyme is extremely low in human livers (Shimada et al., 1994), and it appears to contribute minimally to the metabolism of pharmaceutical products.”
Background
Cytochrome P450 2E1 and its roles in disease
Guengerich, F. P. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109056 · Cited by 114
“The concentration of human P450 2E1 does vary considerably (≥ 10-fold) [106-108].”
BackgroundSelf-citation
Structures of cytochrome P450 3A4
Scott, E. E., & Halpert, J. R. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.004 · Cited by 114
Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance
Sirot, E. J., van der Velden, J. W., Rentsch, K., Eap, C. B., & Baumann, P. (2006) · Drug Safety · doi:10.2165/00002018-200629090-00001 · Cited by 112
Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers
Yamazaki, H., & Shimada, T. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00304-3 · Cited by 113
Self-citation
Cytochrome P450 Sex Differences in Minipigs and Conventional Pigs
Skaanild, M. T., & Friis, C. (1999) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1999.tb00088.x · Cited by 114
Genetic Polymorphism in CYP2E1: Population Distribution of CYP2E1 Activity
Neafsey, P. J., Ginsberg, G., Hattis, D. B., Johns, D. O., Guyton, K. Z., & Sonawane, B. R. (2009) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937400903158359 · Cited by 115
“Data in Caucasians and Japanese suggest that its contribution is between 5 and 10% (Inoue et al., 2000; Shimada et al., 1994).”
Background
Untitled work
(1997) · PubMed · Cited by 114
Hepatic Cytochrome P450 Activity, Abundance, and Expression Throughout Human Development
Sadler, N., Nandhikonda, P., Webb‐Robertson, B., Ansong, C. K., Anderson, L. N., Smith, J. N., CORLEY, R. A., & Wright, A. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.068593 · Cited by 116
“Though minimally expressed in the adult, P450 2D6 accounts for the oxidative metabolism of ;12% of all clinical drugs (Shimada et al., 1994).”
Background
Cytochrome P450: genotype to phenotype
Waring, R. H. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1648911 · Cited by 115
“…within families 1, 2 and 3 account for 93% of the cytochrome P450-mediated foreign compound metabolism with CYP2C8/9, CYP2C19, CYP2D6 and CYP3A4 contributing over 50% of this activity (Lynch & Price, 2007; McGraw & Waller, 2012; Preissner et al., 2013; Shimada et al., 1994; Zhou et al., 2009).”
Background
Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species
van Groen, B. D., Nicolaï, J., Kuik, A. C., Cruchten, S. J. M. V., Peer, E. M. V., Smits, A., Schmidt, S., de Wildt, S. N., Allegaert, K., Schaepdrijver, L. D., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000071 · Cited by 112
Fecal and urinary excretion of aflatoxin B 1 metabolites (AFQ 1 , AFM 1 and AFB‐N 7 ‐guanine) in young Chinese males
Mykkänen, H. M., Zhu, H., Salminen, E. K., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.20951 · Cited by 113
Diazinon Is Activated by CYP2C19 in Human Liver
Kappers, W. A., Edwards, R. J., Murray, S., et al. (2001) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2001.9294 · Cited by 113
Drug metabolism and drug interactions in the elderly
Herrlinger, C., & Klotz, U. E. (2001) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2001.0249 · Cited by 113
Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Zhang, J., Tian, Q., & Zhou, S. (2006) · Current Drug Therapy · doi:10.2174/157488506775268515 · Cited by 113
Cytochrome P450 Enzymes
Harvey, A. T., & Preskorn, S. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199608000-00002 · Cited by 113
ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters
Gleeson, M. P., Bravi, G., Modi, S. P., & Lowe, D. M. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.07.002 · Cited by 111
Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs
Greenblatt, D. J., & Moltke, L. L. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008323754 · Cited by 112
“While one study asserts a large difference in CYP3A expression between liver samples obtained from men and women,(33) the majority of published reports find minimal or no gender differences in hepatic or enteric CYP3A expression/activity.(34-42) In any case, in vitro studies have the intrinsic limitations of confoundi…”
Result
Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery
Riley, R. J., Parker, A. J., Trigg, S., & Manners, C. N. (2001) · Pharmaceutical Research · doi:10.1023/a:1011085411050 · Cited by 114
Monospecific Antipeptide Antibody to Cytochrome P-450 2B6
Stresser, D. M., & Kupfer, D. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15215-4 · Cited by 111
“The reasons for this are not certain, but ethnicity appears to play a role (Kirby et al., 1993; Shimada et al., 1994; Kim et al., 1997).”
Expression of Human Cytochrome P450 2B6 in Escherichia coli: Characterization of Catalytic Activity and Expression Levels in Human Liver
Hanna, I. H., Reed, J. R., Guengerich, F. P., & Hollenberg, P. F. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1708 · Cited by 112
Self-citation
Pharmacokinetic Interactions between Drugs and Botanical Dietary Supplements
Sprouse, A. A., & van Breemen, R. B. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066902 · Cited by 116
“, alprazolam, benzphetamine and diazepam) (Shimada et al. 1994), the CYP3A enzymes show broad substrate specificity.”
Background
Cooperative properties of cytochromes P450
Denisov, I. G., Frank, D. J., & Sligar, S. G. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.011 · Cited by 111
“Although CYP3A4 is the most abundant hepatic P450 (Shimada et al., 1994), effects of other P450 isoforms cannot be excluded, particularly those of CYP3A5, which is 83% identical to CYP3A4, when working with human liver microsomes (McConn et al., 2004).”
Background
Phenotype–genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles
Rodríguez‐Antona, C., Sayi, J., Gustafsson, L. L., Bertilsson, L., & Ingelman‐Sundberg, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.020 · Cited by 111
microRNAs as Mediators of Drug Toxicity
Yokoi, T., & Nakajima, M. (2012) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140250 · Cited by 111
Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function
Uno, Y., Iwasaki, K., Yamazaki, H., & Nelson, D. R. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2010.549492 · Cited by 109
“In the macaque CYP2ABFGST cluster, gene arrangement is different from the human genome (Figure 2A) due to species-specific inversion, insertion, and duplication of genomic segments (Hoffman and Hu, Drug Metabolism Reviews 2007).”
InfluentialSelf-citation
Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin
Park, J.-E., Kim, K.-B., Bae, S. K., et al. (2008) · Xenobiotica · doi:10.1080/00498250802334391 · Cited by 110
“The present study adapted the data of immunologically determined P450 isoform liver contents reported by other researchers (Wrighton et al. 1990; Shimada et al. 1994), i.”
MethodInfluential
IN VITRO METABOLISM OF NAPHTHALENE BY HUMAN LIVER MICROSOMAL CYTOCHROME P450 ENZYMES
Cho, T. M., Rose, R. L., & Hodgson, E. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005785 · Cited by 110
“Total P450 protein content of the 1A2 isoform in human liver ranges from approximately 8 to 13% (Shimada et al., 1994; Rodrigues, 1999).”
Background
Drug metabolism by flavin-containing monooxygenases of human and mouse
Phillips, I. R., & Shephard, E. A. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1239718 · Cited by 111
“The amount of FMO3 in adult human liver [31] is ~ 60% of that of CYP3A4 [35], the most abundant hepatic CYP, which catalyzes almost 30% of all oxidoreduction reactions undergone by drugs [4].”
Background
Symposium Article: Molecular and Physical Mechanisms of First-Pass Extraction
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15271-3 · Cited by 109
Understanding the pharmacokinetics of anxiolytic drugs
Altamura, A. C., Moliterno, D., Paletta, S., Maffini, M., Mauri, M. C., & Bareggi, S. R. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.759209 · Cited by 110
“However, since CYP3A4 is more abundant than CYP2B6 in the human liver [55], the former seems to be the main metabolizing cytochrome of clotiazepam.”
Background
SELECTIVE INHIBITION OF CYP2B6-CATALYZED BUPROPION HYDROXYLATION IN HUMAN LIVER MICROSOMES IN VITRO
Turpeinen, M., Nieminen, R. M., Juntunen, T., Taavitsainen, P., Raunio, H., & Pelkonen, O. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.626 · Cited by 108
Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A
Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Venkatakrishnan, K., Schmider, J., Harmatz, J. S., & Shader, R. I. (1998) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1998.tb06914.x · Cited by 108
High‐throughput screening for stability and inhibitory activity of compounds toward cytochrome P450‐mediated metabolism
Ansede, J. H., & Thakker, D. R. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10545 · Cited by 109
Measurement of Cytochrome P450 Gene Induction in Human Hepatocytes using Quantitative Real-Time Reverse Transcriptase-Polymerase Chain Reaction
Bowen, W. P., Carey, J. E., Miah, A., McMurray, H. F., Munday, P. W., James, R. S., Coleman, R. A., & Brown, A. M. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15348-2 · Cited by 109
“To date, the most widely used model system has been cultured human primary hepatocytes, because they contain a full complement of CYPs, together with the appropriate receptors, drug response elements, and transcriptional factors (Strom et al., 1996).”
Influential
Update Information on Drug Metabolism Systems— 2009, Part II. Summary of Information on the Effects of Diseases and Environmental Factors on Human Cytochrome P450 (CYP) Enzymes and Transporters
Rendić, S., & Guengerich, F. P. (2010) · Current Drug Metabolism · doi:10.2174/138920010791110917 · Cited by 111
Self-citation
Heterologous Expression and Kinetic Characterization of Human Cytochromes P-450: Validation of a Pharmaceutical Tool for Drug Metabolism Research
Masimirembwa, C. M., Otter, C. A., Berg, M., Jönsson, M., Leidvik, B., Jonsson, E., Johansson, T., Bäckman, A., Edlund, A., & Andersson, T. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15034-9 · Cited by 106
“The relative abundance of the hepatic CYPs has been determined as: CYP1A2 (13%), 2A6 (4%), 2B6 ( ,1%), 2C (20%), 2D6 (2%), 2E1 (7%), and 3A4 (30%) (Shimada et al., 1994; Rendic and Carlo, 1997).”
Acetaminophen hepatotoxicity: An update
McClain, C. J., Price, S., Barve, S. S., Devalarja, R., & Shedlofsky, S. I. (1999) · Current Gastroenterology Reports · doi:10.1007/s11894-999-0086-3 · Cited by 103
Absorption, Distribution, Metabolism and Excretion Pharmacogenomics of Drugs of Abuse
Meyer, M. R., & Maurer, H. H. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.171 · Cited by 106
Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo
Zhang, H.-F., Gao, N., Tian, X., Liu, T., Fang, Y., Zhou, J., Wen, Q., Xu, B., Qi, B., Gao, J., et al. (2015) · Scientific Reports · doi:10.1038/srep17671 · Cited by 110
Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects
Ulvestad, M., Skottheim, I. B., Jakobsen, G. S., Bremer, S., Molden, E., Åsberg, A., Hjelmesaeth, J. S., Andersson, T. B., Sandbu, R., & Christensen, H. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.261 · Cited by 106
Review and Evaluation of the Potential Impact of Age- and Gender-Specific Pharmacokinetic Differences on Tissue Dosimetry
M.A., H. J. C. I., Teeguarden, J., McDonald, T. B., Sarangapani, R., Lawrence, G., Covington, T. R., Gentry, R., & Shipp, A. M. (2002) · Critical Reviews in Toxicology · doi:10.1080/20024091064264 · Cited by 107
The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition
Michaud, V., Bar-Magen, T., Turgeon, J., Flockhart, D. A., Desta, Z., & Wainberg, M. A. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005553 · Cited by 106
“It is quite common to observe up to a 40-fold (even 90-fold) interindividual variation in expression of this protein (de Waziers et al., 1990; Shimada et al., 1994; Paine et al., 1997; Wolbold et al., 2003).”
Background
A Skin-Like Cytochrome P450 Cocktail Activates Prohaptens to Contact Allergenic Metabolites
Bergström, M. A., Ott, H., Carlsson, A., et al. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700638 · Cited by 106
“This liver-like rhCYP cocktail is based on data of the amounts of individual CYP enzymes and total CYP content in human liver microsomes (Shimada et al., 1994; Friedberg et al., 1999; Schmitt et al., 2006).”
Background
Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation.
Bailey, D. G., Arnold, J. M. O., Bend, J. R., et al. (1995) · PubMed · Cited by 106
Human cytochrome P450s: selectivity and measurement in vivo
Smith, D. A., ABEL, S. M., Hyland, R., & Jones, B. C. (1998) · Xenobiotica · doi:10.1080/004982598238859 · Cited by 105
Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells
Ulvestad, M., Nordell, P., Asplund, A., Rehnström, M., Jacobsson, S., Holmgren, G., Davidson, L., Brolén, G., Edsbagge, J., Björquist, P., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.029 · Cited by 108
“However, investigating the mRNA expression of the CYP1A and 3A enzyme families revealed that hESC-Hep and hiPSC-Hep differ from hphep in some aspects: hESCHep and hiPSC-Hep expressed only low levels of CYP1A2 and CYP3A4 which are the mayor isoenzymes found in adult hepatocytes [35].”
Background
Physiological Content and Intrinsic Activities of 10 Cytochrome P450 Isoforms in Human Normal Liver Microsomes
Zhang, H.-F., Wang, H.-H., Gao, N., Wei, J., Tian, X., Zhao, Y., Fang, Y., Zhou, J., Wen, Q., Gao, J., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233635 · Cited by 110
“Primers for CYP2A6 and CYP2D6 were designed by Takara Bio Inc. (Dalian, China), and other primers were from the literature (Nishimura et al., 2002; Wang et al., 2011a) (Supplemental Table 2).”
BackgroundMethodResultInfluential
Comparison of basal gene expression profiles and effects of hepatocarcinogens on gene expression in cultured primary human hepatocytes and HepG2 cells
Harris, A. J., Dial, S. L., & Casciano, D. A. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2003.11.014 · Cited by 109
Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer.
Hirvonen, A. (1999) · Environmental Health Perspectives · doi:10.1289/ehp.99107s137 · Cited by 105
7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes
Yamazaki, H., Inoue, K., Mimura, M., Oda, Y., Guengerich, F. P., & Shimada, T. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02178-7 · Cited by 106
Self-citation
Roles of Cytochromes P450 1A2, 2A6, and 2C8 in 5-Fluorouracil Formation from Tegafur, an Anticancer Prodrug, in Human Liver Microsomes
Komatsu, T., Yamazaki, H., Shimada, N., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13674-4 · Cited by 105
“It has been shown that there are interindividual variations in the levels of individual P450 enzymes in humans (Shimada et al., 1994).”
Self-citation
Three-Dimensional Quantitative Structure Activity Relationship Analyses of Substrates for CYP2B6
Ekins, S., Bravi, G., Ring, B. J., Gillespie, T. A., Gillespie, J. S., VandenBranden, M. R., Wrighton, S. A., & Wikel, J. H. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37919-4 · Cited by 104
“2%) (Shimada et al., 1994), its ability to catalyze the oxidation of xenobiotics may have been underestimated (Ekins et al.”
Absolute protein quantification of clinically relevant cytochrome P450 enzymes and UDP-glucuronosyltransferases by mass spectrometry-based targeted proteomics
Gröer, C., Busch, D., Patrzyk, M., et al. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.08.016 · Cited by 104
Human Cytochrome P450 Maximal Activities In Pediatric versus Adult Liver
Blanco, J. G., Harrison, P. L., Evans, W. E., & Relling, M. V. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15052-0 · Cited by 102
“A lack of relationship between age and hepatic microsomal P450 activity (Shimada et al., 1994) or NADPH cytochrome P450 reductase (Schmucker et al.”
Background
Protective effects of coffee diterpenes against aflatoxin B1-induced genotoxicity: mechanisms in rat and human cells
Cavin, C., Macé, K., Offord, E., & Schilter, B. (2001) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(00)00168-x · Cited by 104
Pharmacogenetics of Analgesics: Toward the Individualization of Prescription
Rollason, V., Samer, C. F., Piguet, V., Dayer, P., & Desmeules, J. A. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.7.905 · Cited by 103
Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing
Kacevska, M., Robertson, G. R., Clarke, S. J., & Liddle, C. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.2.137 · Cited by 104
“CYP3A4, the predominant CYP enzyme expressed in human liver, comprises up to 60% of total hepatic CYP protein [1] .”
Background
Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa, M., Shindo, M., & Shimada, T. (2001) · PubMed · Cited by 104
Self-citation
The myotoxicity of statins
Evans, M., & Rees, A. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200208000-00009 · Cited by 104
Sex Differences in the Drug Therapy for Oncologic Diseases
Schmetzer, O., & Flörcken, A. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-30726-3_19 · Cited by 104
Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity
Xuan, J., Chen, S., Ning, B., Tolleson, W. H., & Guo, L. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.10.009 · Cited by 103
Database for Physiologically Based Pharmacokinetic (PBPK) Modeling: Physiological Data for Healthy and Health-Impaired Elderly
Thompson, C. M., Johns, D. O., Sonawane, B. R., et al. (2008) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937400802545060 · Cited by 101
“Shimada et al. (1994) analyzed liver samples from 60 individuals aged 12 to 73 yr (30 Japanese and 30 Caucasian patients) for the content and activities related to CYP 1A2, 2A6, 2B6, 2C, 2D6, 2E1, and 3A.”
Background
Erythromycin-felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice*
Bailey, D. G., Bend, J. R., Arnold, J. M. O., et al. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90163-0 · Cited by 101
Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk
M.A., H. J. C. I., & Andersen, M. E. (1996) · Toxicology · doi:10.1016/0300-483x(96)03385-9 · Cited by 101
The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis
Koonrungsesomboon, N., Khatsri, R., Wongchompoo, P., & Teekachunhatean, S. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-017-0011-3 · Cited by 100
“Cytochrome P450 family 1 subfamily A member 2 (CYP1A2) is a major drug-metabolizing enzyme in the human liver, accounting for ~13–15% of the total cytochrome P450 enzyme [1].”
The Role of CYP3A in Health and Disease
Klyushova, L. S., Perepechaeva, M. L., & Grishanova, A. Y. (2022) · Biomedicines · doi:10.3390/biomedicines10112686 · Cited by 109
Differential Effects of Fluvoxamine and Other Antidepressants on the Biotransformation of Melatonin
Härtter, S., Wang, X., Weigmann, H., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00008 · Cited by 100
Involvement of human liver cytochrome P4502B6in the metabolism of propofol
Oda, Y., Hamaoka, N., Hiroi, T., Imaoka, S., Hase, I., TANAKA, K. A., Funae, Y., Ishizaki, T., & Asada, A. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.00344.x · Cited by 99
Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics
JOHNSON, A., WANG, D., & SADEE, W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.001 · Cited by 97
“CYP2D6 is the most polymorphic cytochrome gene, constitutes 2% of total hepatic cytochrome P450 content (Shimada et al., 1994; Imaoka et al., 1996), and supports oxidative metabolism of more than 70 pharmaceuticals.”
Background
Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity
Loboz, K. K., Gross, A. S., WILLIAMS, K., Liauw, W., Day, R. O., Blievernicht, J., Zanger, U. M., & McLachlan, A. J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.010 · Cited by 98
Quantitation of cytochrome P450 mRNA levels in human skin
Yengi, L. G., Xiang, Q., Pan, J., Scatina, J., Kao, J., Ball, S. E., Fruncillo, R. J., Ferron‐Brady, G., & Wolf, C. R. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(03)00042-3 · Cited by 101
Functionally Defective or Altered CYP3A4 and CYP3A5 Single Nucleotide Polymorphisms and Their Detection with Genotyping Tests
Lee, S., & Goldstein, J. A. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.4.357 · Cited by 100
The CYP2 family: models, mutants and interactions
LEWIS, D. F. V. (1998) · Xenobiotica · doi:10.1080/004982598239236 · Cited by 97
Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation
Weaver, R., Graham, K. S., Beattie, I. G., & Riley, R. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.955 · Cited by 97
“However, it is estimated that 30% of human P450 isoforms remain uncharacterized (Shimada et al., 1994; Lewis, 2000) and true selective substrates for a single P450 isoform have proven to be elusive.”
Background
Design and Development of Novel Composites Containing Nickel Ferrites Supported on Activated Carbon Derived from Agricultural Wastes and Its Application in Water Remediation
Saleh, T. S., Badawi, A. K., Salama, R. S., et al. (2023) · Materials · doi:10.3390/ma16062170 · Cited by 97
“Additionally, it has a carcinogenic effect towards animals and human beings [6].”
Background
Population pharmacokinetics of nevirapine in an unselected cohort of HIV‐1‐infected individuals
de Maat, M. M. R., Huitema, A. D. R., Mulder, J. W., et al. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01657.x · Cited by 97
Three haplotypes associated with CYP2A6 phenotypes in Caucasians
Haberl, M., Anwald, B., Klein, K., Weil, R., Fu, C. T., Gepdíremen, A., Zanger, U. M., Meyer, U., & Wojnowski, L. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000171517.22258.f1 · Cited by 97

Authors: Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P.
Affiliations: Osaka Prefectural Institute of Public Health (JP)
ORCID: Shimada, T
Yamazaki, H
Guengerich, F P
Venue: The Journal of Pharmacology and Experimental Therapeutics
Publisher: Elsevier BV
Published: 1994-07
Volume: 270
Issue: 1
Pages: 414-423
ISSN: 0022-3565 (ISSN-L)
DOI: 10.1016/s0022-3565(25)22379-5
OpenAlex: W2155268095
Cited by: 2,785
References: 0
Citations by year: 2026: 14 · 2025: 28 · 2024: 24 · 2023: 40 · 2022: 36 · 2021: 55 · 2020: 41 · 2019: 59 · 2018: 52 · 2017: 53 · 2016: 75 · 2015: 81 · 2014: 121 · 2013: 104 · 2012: 118
FWCI: 64.47
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
PubMed (publishedVersion)
PubMed
Funders: National Institutes of Health (5r35ca044353-14)
National Cancer Institute (CA 44353)
National Institute of Environmental Health Sciences (ES00267)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Physical Sciences › Chemistry › Inorganic Chemistry › Metal-Catalyzed Oxygenation Mechanisms
Keywords: cytochrome P450, interindividual variability, liver microsomes, CYP1A2, CYP2A6, CYP2B6, CYP2C, CYP2D6, CYP2E1, CYP3A4, monooxygenase activity, procarcinogen metabolism, drug metabolism, sex differences
MeSH terms: Adolescent, Adult, Aged, Aging, Biotransformation, Carcinogens, Child, Cytochrome P-450 Enzyme System, Pharmaceutical Preparations, Female, Humans, Individuality, Infant, Isoenzymes, Japan, Liver, Male, Microsomes, Liver, Middle Aged, Oxidation-Reduction, Sex Factors, Hazardous Substances, White People

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks